News Quantified

Stock Stats

News Stats


All News	{{AllNewsCount}}
News Wires	{{NewsWiresCount}}
Media Monitoring	{{MoreOverCount}}
SEC Edgar Filings	{{SecEdgarFilingsCount}}
Upgrades	{{UpgradesCount}}
Downgrades	{{DowngradesCount}}
Initiated	{{InitiatesCount}}
Reiterated	{{ReiteratesCount}}
Last Earnings	{{LastEarnings}}
Last Earnings EPS	{{LastEps}}
Next Earnings	{{NextEarnings}}

Order Stats

Sub-Penny
{{SubPennyStr}}
Odd Lot
{{OddLotStr}}
Avg. bid-ask spread

{{GetAvgBidAskSpreadForScale}}
Avg. bid / ask size
{{GetAvgBidSizeForScale}} {{GetAvgAskSizeForScale}}

Shares at ask / bid
{{SharesAtAsk_AMP_Str}} {{SharesAtBid_AMP_Str}}
Off exchange
{{OffExchange}}

News

Harrow (NASDAQ:HROW) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.

OSRX Confirms Ongoing Licensing and Availability of Compounded Ophthalmic Medications in California

Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong Growth

Harrow: Revisiting This Eyecare Growth Story Ahead Of Q4 Update [Seeking Alpha]

Breakeven Is Near for Harrow, Inc. (NASDAQ:HROW) [Yahoo! Finance]

11/10/2025

04:05 pm

hrow

13.5%

BEAT

8/11/2025

04:01 pm

hrow

6.1%

BEAT

5/8/2025

04:01 pm

hrow

3.4%

MISS

Form 4 HARROW, INC. For: Jan 30 Filed by: Sullivan Patrick William

Form 3 HARROW, INC. For: Jan 30 Filed by: Sullivan Patrick William

Form 8-K HARROW, INC. For: Jan 30

Form 4 HARROW, INC. For: Jan 06 Filed by: Opaleye Management Inc.

Form 4 HARROW, INC. For: Dec 12 Filed by: BOLL ANDREW R.

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}